Clinical Trials Browser

Phase 1 × Terminated × Pemetrexed × Clear all

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00979576 2025-03-06

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

19 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05241873 2025-02-10

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Phase 1 Terminated

Adenocarcinoma, Brain Neoplasms, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02707666 2024-07-31

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Phase 1 Terminated

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04022876 2022-10-10

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02838745 2022-03-31

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase 1 Terminated

Advanced Cancers

NCT00310050 2018-11-30

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 1 Terminated

4 enrolled 7 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01445392 2018-08-03

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT02083679 2016-10-25

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

Phase 1 Terminated

15 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00907179 2015-07-22

Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01714037 2015-04-08

HALO

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01187615 2014-07-08

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT01373463 2012-07-26

CisPemXetSrg

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00733031 2010-12-10

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Phase 1 Terminated

Neoplasms

NCT00179699 2005-11-07

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung